Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings
Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry diseases
Discussions will feature the following speakers and topics:
Gregory P. Strauss, Ph.D., Assistant Professor; Director: Clinical Affective Neuroscience Laboratory; Director: Georgia Psychiatric Risk Evaluation Program; Department of Psychology, University of Georgia: The trans-diagnostic approach to treating negative symptoms in CNS/psychiatric diseases Remy Luthringer, Ph.D., Executive Chairman and Chief Executive Officer, Minerva Neurosciences, Inc.: Update on Phase 3 clinical trial with roluperidone and BDNF in CNS diseases, including a review of recent BDNF data with roluperidone Jay Saoud, Ph.D., Senior Vice President, Head of Research and Development, Minerva Neurosciences, Inc.: Summary of single-dose escalation study with roluperidone
Minerva expects to report top-line results from the 12-week double blind phase of an ongoing Phase 3 trial with roluperidone (MIN-101) as monotherapy to treat negative symptoms in patients diagnosed with schizophrenia in mid-2019.
Institutional investors and analysts may RSVP to firstname.lastname@example.org.
Interested parties may access the live video webcast of this presentation by visiting the Investors & Media section of Minerva’s website at www.minervaneurosciences.com. A webcast replay of the presentation will be posted on the Minerva website approximately two hours after the event.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone; the timing and scope of future clinical trials and results of clinical trials with roluperidone; the clinical and therapeutic potential of roluperidone; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the
VP, Investor Relations/
Source: Minerva Neurosciences, Inc